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Background: A population-based case-control study was designed to assess changes of serum
levels of immunoglobulins and IgG subclasses between infected and convalescent phase in
community-acquired pneumonia (CAP).
Methods: Over a 2-year period, all subjects who were >14 years of age living in the Maresme
region (Barcelona, Spain) diagnosed of CAP were registered. Controls were healthy subjects
selected from the municipal census. Prognostic factors were assessed and serum levels of total
IgG, IgA, IgM, and IgG subclasses were measured at diagnosis and 1 month later (cases).
Results: We studied 171 patients with CAP and 90 controls. All immunoglobulins were signifi-
cantly lower in cases than in controls. At diagnosis, 42.7% of cases showed low levels of some
immunologic parameter, mainly total IgG and IgG2. Low immunoglobulin levels at diagnosis
were more frequent in patients requiring in-patient care and in those with pneumonia of other
etiology than Streptococcus pneumoniae. In the convalescent phase, 26 (23.6%) patients
normalized immunological levels. In 27 (24.5%) cases, some parameter with low levels per-
sisted especially in patients with etiology of CAP other than S. pneumoniae.
Conclusions: Low serum levels of immunoglobulins particularly total IgG and IgG2 were a com-
mon finding in patients with CAP compared to healthy controls. Low immunoglobulin levels
may be related to CAP prognosis and persisted in the convalescent phase in one-fourth of
cases.
ª 2013 Elsevier Ltd. All rights reserved.
onia 2039Introduction
Community-acquired pneumonia (CAP) remains an important
cause of morbidity and mortality in industrialized countries.
In the general adult population, the annual incidence of CAP
ranges between 1.6 and 13.4 cases per 1000 inhabitants
[1,2], 22e51% of which requiring in-patient care, with a
lethality of 3e25% [3,4]. The mortality rate varies between
0.1 and 0.7 per 1000 persons-year [1,5].
In the small numberofpopulation-basedstudies carriedout
in patients with CAP, neither the occurrence of CAP nor the
outcome of patients in relation to serum levels of immuno-
globulins and IgGsubclasseshasbeen investigated.Although in
patients with recurrent pneumonia, hypogammaglobulinemia
and low levels of IgG subclasses have been reported [6,7], the
true incidence of low values of immunoglobulins and/or IgG
subclasses during an episode ofCAPaswell as in relation to the
severity of pneumonia is unknown.
The objective of this population-based case-control
study was to assess serum levels of immunoglobulins and
IgG subclasses in a sample of patients diagnosed of CAP.
Serum levels at the time of diagnosis were compared with
those obtained in a group of healthy subjects without CAP,
and changes between serum levels at diagnosis and after 30
days were evaluated. The relationship between prognostic
factors and clinical outcome and serum levels of immuno-
globulins at diagnosis and during the convalescent phase
was also analyzed.
Patients and methods
Design and setting
The study was conducted in a mixed residential-industrial
urban area of the Maresme region at the Mediterranean
coast in Barcelona, Spain. On a daily basis, all subjects >14years of age living in the area (an annual population size of
74,368 inhabitants) with CAP diagnosis were assessed. All
physicians working in public primary health care centers
and private clinics of the Maresme region participated in
the reporting of cases. Details of this study have been
previously published elsewhere [8,9].Patients (cases) and controls
Predefined criteria for case registration were based on
acute lower respiratory tract infection for which antimi-
crobials had been prescribed in association with the
appearance of previously unrecorded focal signs of physical
examination of the chest [1] and new radiologic findings
suggestive of pulmonary infiltrate, which was required for
all suspected cases. Patients with aspiration pneumonia
(witnessed aspiration with respiratory symptoms or oral
content aspiration) or active pulmonary tuberculosis, and
patients coming from nursing homes or having being dis-
charged from hospital <7 days before the onset of symp-
toms were excluded from the study. Other exclusion
criteria were congenital hypogammaglobulinemia, admin-
istration of polyclonal intravenous immunoglobulins in the
previous 3 months, and patients with underlying diseases
associated with secondary immune deficiencies including
parenteral treatment of immunosuppressant agents and/or
corticosteroids, active malignancy, infection by the human
immunodeficiency virus (VIH), chronic liver disease,
protein-losing enteropathy, and nephrotic syndrome.
A clinico-radiologic evaluation on enrollment, at 5 days,
and at 30 days or until complete healing was performed in
all patients.
For each case, a control healthy subject was recruited.
Control subjects were randomly selected from themunicipal
census and were matched by age (5 years), sex, and place
of residence. All controls gave written informed consent to
2040 M.C. de la Torre et al.draw a blood sample for the immunologic study and to be
interviewed to collect data on the study variables.
Immunologic study
Blood samples were obtained from all patients at the time
of diagnosis of CAP (acute phase) and in some of the pa-
tients, a new blood sample was drawn after 30 days
(convalescent phase). In controls, blood samples were ob-
tained at the time of the personal interview. In all cases,
samples were stored at 80 C until analysis. Serum total
IgG, IgA, and IgM levels were measured by kinetic nephe-
lometry (Array Protein System; Beckman Instruments, Brea,
CA, USA) and serum IgG subclasses by enzyme-linked
immunosorbent assay [10].
Because normal values of serum concentration of im-
munoglobulins or IgG subclasses in CAP patients were un-
known, conservative cut-points for defining low levels in
‘cases’ were based on the lowest values obtained in ‘con-
trols’, which were 30 mg/dL for IgM, 50 mg/dL for IgA,
680 mg/dL for IgG, 323 mg/dL for IgG1, 154 mg/dL for IgG2,
10 mg/dL for IgG3, and 5 mg for IgG4. Hypogammaglobu-
linemia was defined as a serum IgG level <500 mg/dL in
analysis performed on the first, second, or both blood
samples [10].
Study variables
Study variables were collected using a reliable question-
naire on CAP-related factors [8], which was administered
directly through a personal interview to cases and controls
by trained young physicians and nurses at home except for
some inpatient subjects who were interviewed at the end
of their hospital stay. Study variables were classified into
prognostic factors, and clinical outcome of CAP. Prognostic
factors included severity of CAP defined by the need of
hospital treatment according to the risk classes defined by
Fine et al. [11] and microbiologic diagnosis of CAP (bacte-
rial, viral, or both as well as CAP caused by Streptococcus
pneumoniae or Chlamydia pneumoniae).
The microbiologic diagnosis of CAP was based on re-
sults of blood cultures and cultures of respiratory tract
secretions (via fiberoptic bronchoscopy, bronchoalveolar
lavage, plugged double catheter) or pleural fluid samples,
as well as on the detection in urine of Legionella pneu-
mophila and S. pneumoniae antigen [9]. An aetiological
diagnosis was also based on 4-fould rise in IgG titers for
respiratory viruses (influenza virus A and B, parainfluenza
virus 1e3, adenovirus, respiratory syncytial virus), and
Chlamydia psittaci, Coxiella burnetti, Mycoplasma
pneumoniae, and L. pneumophila between paired serum
samples obtained within 30 days.
Clinical outcome of CAP was obtained from revision of the
patient’s medical record and included length of hospital
stay, number of days to clinical healing (disappearance of all
clinical symptoms), and number of days to return to normal
daily activities (days to return to work in employed patients).
The study protocol was approved by the Ethics Com-
mittee of the Consorci Sanitari del Maresme (Barcelona,
Spain) and all participants gave written informed consent
before enrollment.Statistical analysis
Firstly, serum levels of immunoglobulins and IgG sub-
classes in cases and controls expressed as median a 5% and
95% percentiles are reported. Differences between cases
and controls were analyzed with the Wilcoxon two-sample
paired signed-rank test. Secondly, the frequency of pa-
tients with CAP and low serum levels of immunoglobulins
and IgG subclasses at diagnosis is described. The analysis
of CAP patients with low levels of immunoglobulins at
diagnosis was limited to total IgG, IgG1, and IgG2 because
of the small frequency of the remaining parameters (4
cases or fewer). The relationship between the percentage
of patients with low serum levels of acute phase immu-
nologic parameters with CAP prognostic factors, and
clinical outcomes were assesses with the Fisher’s exact
test for the categorical variables and the Wilcoxon two-
sample paired signed-rank test or the KruskaleWallis test
for continuous variables. Finally, patients were grouped
into “normalenormal”, “low levelsenormal levels” and
“low levelselow levels” according to changes of the
immunologic status from diagnosis to convalescence. The
relationship between these three patterns of progression
with etiology, prognostic factors, and clinical outcomes
was analyzed using the Fisher’s exact test and the Wil-
coxon two-sample paired signed-rank test or the Krus-
kaleWallis test as needed. Statistical significance was set
at P < 0.05.
Results
Study population and salient findings
A total of 241 patients, 140 men with a mean (standard
deviation, SD) age of 55 (21) years and 101 women with a
mean age of 51 (21) years, received a diagnosis of CAP.
Seventy (29%) patients were excluded for the following
reasons: immunosuppressive therapy in 21, HIV seroposi-
tivity in 17, chronic liver disease in 13, active malignancy
in 5, death prior to blood sampling in 6, serum invalid
blood sample in 5, and inability to contact the patient
after diagnosis in 3. Participation in the study was pro-
posed to 171 healthy subjects, 81 of which (47.4%) refused
(Fig. 1).
The study population included 171 cases (94 men with a
mean [SD] age of 53.8 [19.6] years and 77 women with a
mean [SD] age of 50.9 [20.7] years) and 90 controls (51 men
with a mean [SD] age of 54.5 [18.5] years and 39 women
with a mean [SDS] age of 52.6 [21.0] years). The distribu-
tion of cases and controls according to sex (PZ 0.9) or age
(P Z 0.6) was not significantly different. Previous CAP was
recorded in 25 cases (14.6%) and 8 controls (8.9%)
(P Z 0.2).
Of the 160 patients with etiologic evaluation, 73 (45.6%)
had an identifiable etiology. There were 47 episodes of
bacterial infection, 20 of viral infection, and 6 of mixed
bacterial and viral infection. S. pneumoniae and C. pneu-
moniae were the most common pathogens and accounted
for 20 and 15 cases, respectively.
A total of 95 patients (55.5%) were admitted to the
hospital. All of them fulfilled the hospitalization criteria of
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Figure 1 Flow-chart of the study population.
IgG in community-acquired pneumonia 2041Fine et al. [11], with a mean (SD) hospital stay of 11.1 (9.7)
days. Twelve patients were admitted to the ICU, and three
of these patients died. The mean (SD) time from diagnosis
to return of daily activities was 22.6 (14.4) days.Serum immunoglobulin levels in cases and controls
At the time of diagnosis, serum levels of total IgG, IgA, and
IgG subclasses IgG1, IgG2 were significantly lower in cases
than in controls (Table 1). Statistical significance was
almost reached for IgG3. Low levels of some immunologic
parameter were observed in 73 (42.7%) patients, with
decreased total IgG values in 51 (29.8%) and decreased IgG2
values in 38 (22.2%). The IgG1 subclass was also low in 19
(11.1%) patients. Low levels of the remaining immuno-
globulins were infrequent (Table 1). Sixty-nine cases
showed low serum levels of total IgG and/or IgG2 subclass,Table 1 Serum immunoglobulins at diagnosis of CAP in cases an
Serum
immunoglobulins
Controls
(n Z 90)
Median (IQR)a
Cases
Median
Total IgG,
mg/dL
1120 (810e1560) 820 (
IgA, mg/dL 245 (90e550) 200 (
IgM, mg/dL 100 (40e250) 110 (
IgG subclasses,
mg/dL
IgG1 651 (403e1017) 521.5 (
IgG2 328.5 (172e560) 240 (
IgG3 52.5 (19e113) 44.5 (
IgG4 38 (5e130) 31 (
a IQR: interquartile range (5the95th percentile).which accounted for 40.3% of cases and 94.5% of all CAP
patients with low immunoglobulins. Hypogammaglobulin-
emia was observed in 18 cases (10.5% of all patients
with CAP).Changes of serum immunoglobulins from the acute
to the convalescent phase
Serum immunoglobulin levels were measured at 30 days
after diagnosis of CAP in 110 (64.3%) of the 171 patients.
Forty patients refused blood sampling or did not attend the
control visit, the blood sample was insufficient or invalid in
18, and 3 patients had died during their stay in the ICU.
Changes of immunologic status from diagnosis to
convalescence according to the groups of “normal-
enormal”, “low levelsenormal levels” and “low lev-
elselow levels” are shown in Fig. 2. Fifty-seven (51.8%)d controls.
(n Z 171)
(IQR)
P value Patients with low
immunoglobulin
levels No. (%)
440e1440) <0.0001 51 (29.8)
70e440) 0.0007 4 (2.3)
40e300) 0.2 3 (1.7)
265e932) <0.0001 19 (11.1)
76e560) <0.0001 38 (22.2)
17e104) 0.05 2 (1.7)
5e137) 0
Figure 2 Progression of serum levels of total IgG and IgG subclasses in 110 patients with CAP from the acute phase of the disease
to convalescence.
2042 M.C. de la Torre et al.patients had normal levels in the acute and convalescent
phases of total IgG or any subclass, 26 (23.6%) patients had
low levels in the acute phase and normal levels in the
convalescent phase, and the remaining 27 (24.5%) had low
levels in the acute and convalescent phases. The per-
centage of patients with hypogammaglobulinemia
decreased from 10.5% in the acute phase to 3.6% at
convalescence. As compared with IgG1 and IgG2 sub-
classes, total IgG was the immunoglobulin fraction with
the highest percentage of patients with low levels in the
acute phase (34.5%) as well as patients who returned to
normal values (18.2%) and patients with persistent low
values (16.3%) during convalescence. The IgG2 subclass
also showed an important percentage of progression to
normal levels (15.6%), with a percentage of patients of 11%
with persistence of low levels. IgG1 was the immunologic
parameter with the lowest percentage of patients
returning to normal values (6.4%) and the lowest per-
centage of patients with low levels at convalescence
(5.5%). In general, approximately half of the patients with
low serum immunoglobulin levels in the acute phase had
persistent low levels in the convalescent phase.Low serum immunoglobulins at diagnosis and
prognostic factors, and outcome of CAP
In relation to prognostic factors, low levels of total IgG
were significantly more frequent in patients who required
hospital admission (P Z 0.01) and in those with etiologies
other than S. pneumoniae (P Z 0.04). Low serum levels of
IgG2 also were significantly more frequent in patients with
etiologies other than S. pneumoniae (PZ 0.008) (Table 2).
There were no statistically significant differences in rela-
tion to outcome variables, including length of hospital stay,
days to clinical healing, days to return to normal activities,
and mortality.Changes of serum immunoglobulins levels from
acute to convalescent phases and prognostic
factors, and outcome of CAP
In relation to prognostic factors, the percentage of patients
with persistent low levels of either IgG2 subclass (PZ 0.01)
or any immunoglobulin (P Z 0.009) was significantly lower
in those with S. pneumoniae or C. pneumoniae etiology
(Table 3). Changes of serum immunoglobulins were unre-
lated to clinical outcome of CAP.Discussion
This population-based study shows for the first time that
serum levels of immunoglobulins are lower in adults with
CAP than in healthy controls, with a prevalence of 42.7%.
The present study had a double objective. On the one
hand, to describe serum levels of immunoglobulins at
different phases of CAP and, on the other, to explore po-
tential associations that may tentatively help clinicians to
establish the prognosis of the disease. Firstly, an important
finding was the high frequency of low serum IgG levels at
the time of diagnosis of CAP. In about 24% of patients,
normalization of these values over the course of the dis-
ease was documented but low immunoglobulin levels per-
sisted during the convalescent phase in a quarter of
patients. Secondly, analysis of the associations between
serum levels of immunoglobulins both at the acute phase
of CAP and during convalescence and prognostic factors,
and clinical outcome was limited by the non-uniform
behavior of some immunoglobulins, such as IgG2 subclass,
and the weight of total IgG in relation to other immuno-
globulins (total IgG is composed by their subclasses and
correlates with IgA and IgM).
On diagnosis of CAP, 42.7% of patients had low levels of
some IgG or IgG subclasses, mainly total IgG (29.8% of cases),
Table 2 Relationship between low serum immunoglobulins at diagnosis and prognostic factors of CAP.
Variables IgG1 IgG2 Total IgG Any immunoglobulin
% patients P value % patients P value % patients P value % patients P value
Severity of CAP
Outpatient care, n Z 79 6.4 0.09 19.2 0.5 20.3 0.01 38.0 0.3
In-patient care, n Z 92 15.2 25.0 38.0 46.7
Etiologic diagnosis
Not studied, n Z 98 13.4 0.9 20.6 0.2 34.7 0.2 42.9 0.2
Bacterial, n Z 47 8.5 21.3 27.7 44.7
Viral, n Z 20 10.0 40.0 20.0 50.0
Mixed viral and bacterial, n Z 6 0 0 0 0
Streptococcus pneumoniae as etiology of CAP
Yes, n Z 20 10.0 1.0 0 0.008 10.0 0.04 15.0 0.008
No, n Z 151 11.3 25.3 32.5 46.4
Chlamydia pneumoniae as etiology of CAP
Yes, n Z 15 0 0.2 26.7 0.7 26.7 1.0 53.3 0.4
No, n Z 156 12.3 21.9 30.1 41.7
IgG in community-acquired pneumonia 2043IgG2 (22.2% of cases), and IgG1 (11.1% of cases). Low levels
persisted in the convalescent phase in 24.5% of patients. In
addition, 10.5% of patients showed IgG levels lower than
500 mg/dL, which persisted during convalescence in 3.6% of
cases. This observation demonstrates the influence of CAPon
decreasing serum levels of immunoglobulins that may be
likely due to a greater consumption due to the infection itself
or to a limited quantitative response in the production of
antibodies against infection [12e14]. The fact that low levels
were predominantly total IgG and IgG2 and that low levels
were found in more severe cases and in those caused by
etiologies other than S. pneumoniae are in favor of the in-
fluence of infection itself. However, the correlation between
absolute IgG levels and protection against infection is un-
known. Also, the absolute level of antibodies measured at
one time point may not simply be the important correlate
with protection against infection, but rather whether there
is an appropriate antibody response to an antigen challenge,
which may remain intact even in individuals with absolute
low IgG levels.
An interesting observation was that low serum immu-
noglobulin levels predominated in patients with CAP due to
causative agents other than S. pneumoniae. Although a
higher severity of CAP in relation to some causative bac-
teria, such as S. pneumoniae in contrast to C. pneumoniae
[15] or viruses [12] has been reported, in a recent study of
the severe pandemic influenza A (H1N1), severe H1N1
infection was associated with immunoglobulin IgG2 subclass
deficiency, which appears to persist in a majority of pa-
tients [16]. These results are consistent with our study, in
which low serum immunoglobulin levels at diagnosis of CAP
seemed to be more frequent in viral than in bacterial in-
fections and in patients without an identifiable etiology.
Patients requiring in-patient care showed lower immu-
noglobulin levels than those treated in the outpatient
setting. Feldman et al. [17] also found a tendency of lower
levels of immunoglobulins in critically ill patients versus
less severely ill. In a pilot study of the time-course of
gammaglobulin concentrations in 21 patients with septic
shock, low concentrations of gammaglobulins, especially
IgG, were common persisted over time even when sepsisresolves. Despite similar presentation, patients with hypo-
IgG had greater vasopressor requirements, were more
likely to develop acute lung injury/acute respiratory
distress syndrome, and had higher mortality [18]. The au-
thors of this study conclude that patients with low IgG
concentrations may represent a logical target group to
study the effects of immunoglobulin supplementation in
septic shock.
Neither the length of hospital stay nor the time from
diagnosis to the return of the everyday activities was
associated with serum immunoglobulin levels at any time of
the episode of pneumonia. However, the fact that low
levels of total IgG were significantly more frequent in pa-
tients who required hospital admission suggests some pre-
dictive value for prognosis.
Our observational study cannot differentiate if the low
levels of immunoglobulins are a cause or a consequence of
the CAP infection. In the first case, the previous immune
deficit would favor the infection. In the second case, low
immunoglobulin levels at the time of diagnosis of CAP may
be related to an increase in consumption during the acute
phase of the illness. Independently of this question, in the
future, it may be contemplated the possibility to treat
patients diagnosed of severe CAP with intravenous immu-
noglobulin [20]. This has been already carried out in some
groups of patients with severe infection [21,22], in which a
reduction of mortality has been achieved especially in
children.
Finally, the presence of transient abnormalities may
suggest defects in the immune response against the bac-
terial aggression, a fact that has not been assessed in this
study but may be the objective of new hypotheses. In this
respect, assessment of the ability to produce antibodies
against specific antigens in patients with persistent low
immunoglobulin levels following CAP may be of help to
confirm the immune defect [19].
In conclusio´n, low serum levels of immunoglobulins
particularly total IgG and IgG2 is a common finding in pa-
tients with CAP. Also, low immunoglobulin levels also may
be related to CAP prognosis and persisted in the convales-
cent phase in one-fourth of cases.
Table 3 Relationship between changes of serum immunoglobulins from the acute phase to convalescence and prognostic factors of CAP.
Variables IgG1 subclass IgG2 subclass Total IgG Any immunoglobulin
Percentage of patients P
value
Percentage of patients P
value
Percentage of patients P
value
Percentage of patients P
valueNormale
normal
Low-
normal
Low-
low
Normale
normal
Low-
normal
Low-
low
Normale
normal
Low-
normal
Low-
low
Normale
normal
Low-
normal
Low-
low
Severity of CAP
Outpatient care,
n Z 52
92.2 2.0 5.9 0.2 74.5 11.8 13.7 0.4 75.0 11.5 13.5 0.1 53.9 21.2 25.0 0.8
In-patient care,
n Z 58
84.5 10.3 5.2 72.4 19.0 8.6 56.9 24.1 19.0 50.0 25.9 24.1
Etiologic diagnosis
Not studied,
n Z 60
86.4 5.1 8.5 0.8 71.2 11.9 17.0 0.3 56.7 23.3 20.0 0.3 45.0 26.7 28.3 0.5
Bacterial,
n Z 33
87.9 9.1 3.0 75.8 21.2 3.0 69.7 12.1 18.2 54.6 21.2 24.2
Viral, n Z 12 91.7 8.3 0 66.7 25.0 8.3 83.3 16.7 0 58.3 25.0 16.7
Mixed viral and
bacterial, n Z 5
100 0 0 100 0 0 100 0 0 100 0 0
Streptococcus pneumoniae as etiology of CAP
Yes, n Z 19 89.5 5.3 5.3 1.0 100 0 0 0.01 89.5 5.3 5.3 0.08 84.2 5.3 10.5 0.009
No, n Z 91 87.8 6.7 5.6 67.8 18.9 13.3 60.4 20.9 18.7 45.1 27.5 27.5
Chlamydia pneumoniae as etiology of CAP
Yes, n Z 8 100 0 0 1.0 62.5 37.5 0 0.2 62.5 37.5 0 0.2 37.5 62.5 0 0.02
No, n Z 102 87.1 6.9 5.9 74.3 13.9 11.9 65.7 16.7 17.7 52.9 20.6 26.5
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